Avadel Pharmaceuticals Under Investigation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 26 Nov 25
Source: PRnewswire
Halper Sadeh LLC is investigating Avadel Pharmaceuticals PLC for potential violations of federal securities laws and breaches of fiduciary duties. This investigation may impact shareholder confidence and stock performance.
The firm encourages shareholders to contact them to discuss their rights, indicating that there may be limited time to enforce these rights. This legal scrutiny comes at a time when the stock has hit a 5-day low, reflecting investor concerns.
As the broader market shows gains, with the Nasdaq-100 up 1.15% and the S&P 500 up 0.96%, Avadel's decline highlights specific issues affecting the company rather than general market trends.
Analyst Views on AVDL
Wall Street analysts forecast AVDL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for AVDL is 20.29 USD with a low forecast of 18.50 USD and a high forecast of 22.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
0 Buy
10 Hold
0 Sell
Hold
Current: 21.560
Low
18.50
Averages
20.29
High
22.50
Current: 21.560
Low
18.50
Averages
20.29
High
22.50
About AVDL
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
